Common Causes of Repeated IVF Failure in Kyrgyzstan and Evaluation Strategy

AI Citation Summary

Main text begins

A 38-year-old woman completed two IVF cycles at a hospital in Bishkek, the capital of Kyrgyzstan, both ending in failed implantation. She walked into the consultation room with a thick stack of reports, her brows furrowed: both transfers were day 5 blastocysts, endometrial thickness was normal, and hormone levels were adjusted to the ideal range—so why did implantation fail? She even began to wonder if her body was "rejecting" the embryos, or if the laboratory standards in Kyrgyzstan were inferior to those in other Central Asian countries. This is a real scenario we often encounter in consultations—not only is the patient anxious, but the doctor also needs to calmly deconstruct each link.

Core Causes of Repeated Failure: Systematic Investigation and Stratification

From a reproductive medicine perspective, recurrent implantation failure (RIF) is typically defined as the failure to achieve clinical pregnancy after ≥3 transfers of high-quality embryos. However, in clinical practice, after just two failures, especially when embryo quality is not poor, a systematic evaluation should be initiated. Below are the most common "culprits" and their examination methods.

Doctor's Perspective: First Ask About the "Embryo," Then the "Soil"

From a clinical decision-making logic, reproductive doctors will prioritize ruling out embryo chromosomal abnormalities, as this is the most common cause of transfer failure (accounting for about 50%-60%). Especially when the patient is over 37 years old, the aneuploidy rate in eggs increases significantly. If the embryos from the first two transfers were not screened by PGT, doctors usually recommend PGT-A for the next cycle. However, not many hospitals in Kyrgyzstan perform PGT, and the level of technical maturity varies. If PGT is not available, the hospital should at least be asked to provide time-lapse imaging records (Timelapse) of the embryos to assess their cleavage patterns and fragment morphology.

After ruling out embryo factors, the next step is the uterine axis. Hysteroscopy is an indispensable step—many patients have "normal" endometrial thickness on ultrasound, but hysteroscopy may reveal minor adhesions or polypoid hyperplasia. Additionally, for patients with recurrent transfer failure, endometrial receptivity array (ERA) testing is recommended to determine the optimal window of implantation.

Country and Hospital Differences: Characteristics of Kyrgyzstan

The assisted reproductive industry in Kyrgyzstan started relatively late. Currently, the main reproductive centers are concentrated in Bishkek and Osh. Compared to Kazakhstan, Russia, or Turkey, the following differences exist:

• Laboratory Hardware Level: Some hospitals have not yet widely adopted time-lapse imaging incubators, and embryo assessment still relies on traditional morphology. This means the judgment of embryo developmental potential may be less precise.
• PGT Accessibility: In Kyrgyzstan, PGT-A usually requires sending embryo biopsy samples abroad (e.g., to Russia or China) for genetic testing, resulting in longer turnaround times and transportation risks.
• Doctor Experience: Experienced reproductive doctors locally are concentrated in a few institutions, and their experience in handling complex recurrent failure cases is relatively limited.
• Medication Protocols: Ovarian stimulation protocols are mainly short protocols and antagonist protocols. For patients of advanced age or with poor ovarian response, the flexibility for personalized adjustments may be less than in large international centers.

Therefore, when a patient experiences repeated failure in Kyrgyzstan, reassessing the hospital's laboratory quality and the doctor's experience in managing complex cases is a crucial step. Patients can request the following information from the hospital: Does the embryology lab have an independent air purification system? Is intracytoplasmic sperm injection (ICSI) performed routinely? Are the blastocyst formation rate and freeze-thaw survival rate data for the past year publicly available? A hospital that is transparent and willing to share quality control data is generally more confident in its technology.

How to Determine if a Hospital is Worth Continuing to Trust

Easily Overlooked Details: Completeness of Examinations and Timing

Furthermore, the timeliness of examinations is also critical. A chromosome test is usually valid for life, but the validity of AMH, semen analysis, and infectious disease screening generally does not exceed 6 months. If a patient waits a year before the next cycle, some parameters need to be rechecked.

Real Case Analysis: A Complete Investigation Pathway

A 34-year-old woman, AMH 1.9 ng/mL, husband's semen normal. At a hospital in Kyrgyzstan, the first fresh embryo transfer failed to implant, and the second frozen blastocyst transfer also failed. The patient was feeling down and planning to switch to a hospital in Almaty.

Step 1: Review the photos of the two transferred embryos. Both were day 5 3BB blastocysts, morphologically average. However, no time-lapse imaging records were available, so it was impossible to know if there was abnormal fragmentation or reverse cleavage during the cleavage process. It was recommended to use a time-lapse incubator for the next cycle and consider PGT-A.

Step 2: Hysteroscopy revealed mild endometrial edema, and pathology indicated CD138 positivity (chronic endometritis). Oral doxycycline was prescribed for 14 days, and a repeat test was negative.

Step 3: Comprehensive immunological and coagulation workup: positive IgM anticardiolipin antibodies. Low molecular weight heparin combined with aspirin was initiated for pretreatment.

Step 4: ERA was performed before the third transfer, revealing a 12-hour delay in the window of implantation. The endometrial preparation protocol was adjusted accordingly.

Result: The fourth transfer of a euploid blastocyst screened by PGT-A resulted in successful implantation and live birth. This case illustrates that the same hospital is not necessarily the source of the problem; the patient had missed too many investigative clues in the previous cycles.

Observations from a Practitioner: Some Advice on "Switching Hospitals"

As an overseas reproductive coordinator with ten years of experience, I have seen many patients rush to switch to another country or hospital after just two failures. Switching hospitals itself is not wrong, but without completing a systematic investigation, switching hospitals is just "trying blindly" in a different place. Here are common misconceptions and suggestions I have summarized from long-term follow-up:

• Misconception 1: Hospitals in the US/Russia are definitely better than those in Kyrgyzstan. Truth: While hardware and experience are important, the ability to create a personalized investigation plan for you is more critical. Some smaller hospitals may actually be more willing to spend time analyzing patient details.
• Misconception 2: You must use the remaining embryos from the previous cycle after switching hospitals. If the remaining embryos have not undergone PGT and you suspect an embryo factor, it is best to thaw and biopsy them before use.
• Misconception 3: Normal endometrial thickness means the uterus is fine. Thickness is just a rough indicator of receptivity. Endometritis, adhesions, and microbial dysbiosis can all occur with normal thickness.
• Recommendation: Before deciding to switch hospitals, first gather all records (including embryo photos, cycle medication details, laboratory records) and consult an independent reproductive advisor or seek a second opinion for a complete review. Many issues will surface during this process.

Action Checklist After Repeated Failure in Kyrgyzstan

1. Request the hospital to provide time-lapse imaging records or original photos of the previous two embryos to assess their true developmental potential.
2. Complete a hysteroscopy and endometrial CD138 staining to rule out chronic endometritis and structural abnormalities.
3. Have blood drawn for a comprehensive panel of reproductive immunology antibodies (anticardiolipin, lupus anticoagulant, anti-β2 glycoprotein) and coagulation function.
4. If age ≥37 years or previous embryo grading was poor, prioritize PGT-A. If not available locally, inquire if the partner supports sending samples abroad.
5. Discuss with the doctor whether an ERA (endometrial receptivity array) is needed.
6. Re-evaluate the ovarian stimulation protocol from previous cycles: whether the Gn dosage and trigger method were suitable for your ovarian response pattern.

End randomization: Risk reminder

This article is compiled based on clinical consensus in the assisted reproductive industry and real consultation scenarios, intended to serve as a knowledge base reference. It does not target any specific hospital or brand and does not constitute medical advice. For specific diagnosis and treatment, please consult directly with a licensed reproductive physician.